The UPCI Chemical Biology Facility (ChBF) has emerged from an innovative UPCI-supported pilot project to become a new Shared Facility. The overall goal ofthe ChBF is to ensure that UPCI members have access to the most modern chemical biology reagents, instrumentation, and personnel, which will enable them to identify unique chemical probes and potential anticancer leads for further optimization. The ChBF will provide high quality support services to UPCI researchers for: 1) high throughput screening (HTS) and high content screening (HCS) assay design, development, validation, and implementation, 2) small molecule and siRNA library distribution, 3) lead characterization and optimization, and 4) data analysis. A component ofthe ChBF's service will include supplying high quality, professional access to multiple automated liquid handlers for use in 96- and 384-well plate formats, detectors, large chemical libraries, siRNA libraries, chemical informatics, chemical analysis, analog acquisition, and sophisticated data analysis software. The ChBF will collaborate with UPCI faculty, staff, and trainees in developing and conducting cancer-relevant, cell-free and cell-based HTS and HCS assays. Training will be offered either on an individual or group basis depending on the perceived need or formal requests for training. Availability of ChBF resources will be disseminated through posts on the UPCI website, emails to UPCI members, and annual workshops, seminars, and poster presentations at the UPCI retreat. The ChBF is especially interested in promoting innovative assays at UPCI. Therefore, it will encourage the development and implementation of challenging cancer-related assays. In particular, the ChBF will promote novel HCS assays focused on targets that have traditionally been considered """"""""undruggable"""""""" as an innovative component of its activity within UPCI. The ChBF creates a starting point for the identification of unique chemical probes and lead structures for potential new therapies for all of UPCI's Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705410
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$123,232
Indirect Cost
$41,711
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Vyas, Avani R; Moura, Michelle B; Hahm, Eun-Ryeong et al. (2016) Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. J Cell Biochem 117:2482-95
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2016) Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol :
Concha-Benavente, Fernando; Srivastava, Raghvendra M; Trivedi, Sumita et al. (2016) Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 76:1031-43
Posluszny, Donna M; Dew, Mary Amanda; Beckjord, Ellen et al. (2016) Existential challenges experienced by lymphoma survivors: Results from the 2010 LIVESTRONG Survey. J Health Psychol 21:2357-66
Delgado, Evan; Boisen, Michelle M; Laskey, Robin et al. (2016) High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol 141:348-56
Kirkwood, Caitlin M; MacDonald, Matthew L; Schempf, Tadhg A et al. (2016) Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration. J Neuropathol Exp Neurol 75:175-82
Chen, Mingqing; Sun, Fan; Han, Lei et al. (2016) Kaposi's sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling. Oncotarget 7:33363-73
Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2016) A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res :
Blundon, Malachi A; Schlesinger, Danielle R; Parthasarathy, Amritha et al. (2016) Proteomic analysis reveals APC-dependent post-translational modifications and identifies a novel regulator of β-catenin. Development 143:2629-40
Rodler, Eve T; Kurland, Brenda F; Griffin, Melissa et al. (2016) Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res 22:2855-64

Showing the most recent 10 out of 885 publications